Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer

Krishnansu S. Tewari,Robert A. Burger,Danielle Enserro,Barbara M. Norquist,Elizabeth M. Swisher,Mark F. Brady,Michael A. Bookman,Gini F. Fleming,Helen Q. Huang,Howard D. Homesley,Jeffrey M. Fowler,Benjamin E. Greer,Matthew P. Boente,Sharon X. Liang,C Ye,Carlos Bais,Leslie M. Randall,John K. C. Chan,J. Stuart Ferriss,Robert L. Coleman,Carol Aghajanian,Thomas J. Herzog,Philip J. DiSaia,Larry J. Copeland,Robert S. Mannel,Michael J. Birrer,Bradley J. Monk

Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer

2019

PURPOSEWe report the final, protocol-specified analysis of overall survival (OS) in GOG-0218, a phase III, randomized trial of bevacizumab in women with newly diagnosed ovarian, fallopian tube, or ...

Keywords:

Randomized controlled trial
Fallopian tube
Bevacizumab
Pathology
Ovarian cancer
Internal medicine
Oncology
Medicine
newly diagnosed
primary treatment
MEDLINE
overall survival

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

132

Citations